Pegfilgrastim Biosimilar Market Size | COVID-19 Impact Analysis | Forecast to 2027
The global pegfilgrastim biosimilar market is expected to grow at a significant CAGR during the forecast period (2021-2027). The global pegfilgrastim biosimilar market is expanding as the number of people diagnosed with various diseases, such as cancer and HIV/AIDS, rises. Pegfilgrastim biosimilars are used to treat low blood neutrophil levels as well as to combat infections in people who have had radiation therapy or chemotherapy. As they are less expensive than pegfilgrastim, pegfilgrastim biosimilar are gaining popularity across the globe. The market is expected to grow rapidly in the next years owing to the increase in the prevalence of HIV/AIDS. As per HIV, Gov, around 5,000 young women between the ages of 15 and 24 get infected with HIV every week across the globe. In 2020, women and girls accounted for 63% of all new HIV infections in Sub-Saharan Africa. Since the peak in 2004, AIDS-related mortality has decreased by 64%, and by 47% since 2010. The AIDS-related disease claimed the lives of roughly 680,000 persons globally in 2020, compared to 1.3 million in 2010.
To Request a Sample of our Report on Pegfilgrastim
Biosimilar Market: https://www.omrglobal.com/request-sample/pegfilgrastim-biosimilar-market
The majority of HIV-positive
people live in low- and middle-income nations. Eastern and southern Africa had
20.6 million HIV-positive people (55%), Asia and the Pacific had 5.7 million
(15%), western and central Africa had 4.7 million (13%), and Western and
Central Europe and North America had 2.2 million (6%). In 2020, there were
roughly 37.7 million HIV-positive people across the globe. There were 36
million adults and 1.7 million children aged 0 to 14 years among them. Women
and girls made up more than half of the participants (53%). Filgrastim drug is
extensively used for the treatment of low levels of blood neutrophils that
occurred due to radiation poisoning, HIV/AIDS, chemotherapy, or another source.
Therefore, rising prevalence of HIV is driving the growth of the market.
Pegfilgrastim biosimilars are expected to be driven by government initiatives
to produce biosimilars. The Australian government is committed to the
Biosimilar Awareness Initiative, and in 2018 they strengthened their commitment
by awarding a $5 million grant to the Generic and Biosimilar Medicines
Association to support increased general biosimilar education and activities
that promote appropriate biosimilar dispensing, prescription, and use.
Market Coverage
• The market
number available for – 2020-2027
• Base
year- 2020
• Forecast
period- 2021-2027
• Segment
Covered-
·
By Application
·
By Distribution Channel
• Regions
covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
•
Competitive Landscape: Pfizer Inc,
Novartis International AG (Sandoz Inc.), and Fresenius SE & Co. KGaA, among
others.
(Get 15% Discount on Buying this Report)
A
full Report of Pegfilgrastim Biosimilar Market is Available @ https://www.omrglobal.com/industry-reports/pegfilgrastim-biosimilar-market
Global Pegfilgrastim Biosimilar Market Report by Segment
By Application
·
Chemotherapy Treatment
·
Transplantation
·
Others
By Distribution Channel
·
Online Pharmacy
·
Hospital Pharmacy
·
Retail Pharmacy
Global Pegfilgrastim Biosimilar Market by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment